IMMUTEP LTD-SP ADR (IMMP)
US45257L1089 - ADR
Overall IMMP gets a fundamental rating of 3 out of 10. We evaluated IMMP against 588 industry peers in the Biotechnology industry. IMMP scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. IMMP does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
In the past year IMMP has reported negative net income.
In the past year IMMP has reported a negative cash flow from operations.
In the past 5 years IMMP always reported negative net income.
In the past 5 years IMMP always reported negative operating cash flow.
1.2 Ratios
IMMP's Return On Assets of -27.06% is fine compared to the rest of the industry. IMMP outperforms 75.43% of its industry peers.
Looking at the Return On Equity, with a value of -29.23%, IMMP belongs to the top of the industry, outperforming 81.57% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -27.06% | ||
| ROE | -29.23% | ||
| ROIC | N/A |
ROA(3y)-31.68%
ROA(5y)-33.84%
ROE(3y)-34.76%
ROE(5y)-43.99%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
IMMP does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
IMMP does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, IMMP has more shares outstanding
IMMP has more shares outstanding than it did 5 years ago.
The debt/assets ratio for IMMP has been reduced compared to a year ago.
2.2 Solvency
An Altman-Z score of 24.78 indicates that IMMP is not in any danger for bankruptcy at the moment.
With an excellent Altman-Z score value of 24.78, IMMP belongs to the best of the industry, outperforming 94.37% of the companies in the same industry.
IMMP has a Debt/Equity ratio of 0.01. This is a healthy value indicating a solid balance between debt and equity.
IMMP has a Debt to Equity ratio of 0.01. This is comparable to the rest of the industry: IMMP outperforms 46.42% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 24.78 |
ROIC/WACCN/A
WACC8.67%
2.3 Liquidity
IMMP has a Current Ratio of 13.81. This indicates that IMMP is financially healthy and has no problem in meeting its short term obligations.
With an excellent Current ratio value of 13.81, IMMP belongs to the best of the industry, outperforming 88.91% of the companies in the same industry.
A Quick Ratio of 13.81 indicates that IMMP has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 13.81, IMMP belongs to the top of the industry, outperforming 89.08% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 13.81 | ||
| Quick Ratio | 13.81 |
3. Growth
3.1 Past
The earnings per share for IMMP have decreased strongly by -19.67% in the last year.
Looking at the last year, IMMP shows a very negative growth in Revenue. The Revenue has decreased by -50.10% in the last year.
Measured over the past years, IMMP shows a very negative growth in Revenue. The Revenue has been decreasing by -51.34% on average per year.
EPS 1Y (TTM)-19.67%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-12.24%
Revenue 1Y (TTM)-50.1%
Revenue growth 3Y-76.04%
Revenue growth 5Y-51.34%
Revenue growth Q2Q-28.01%
3.2 Future
Based on estimates for the next years, IMMP will show a very strong growth in Earnings Per Share. The EPS will grow by 48.06% on average per year.
Based on estimates for the next years, IMMP will show a small growth in Revenue. The Revenue will grow by 3.12% on average per year.
EPS Next Y27.02%
EPS Next 2Y27.62%
EPS Next 3Y36.63%
EPS Next 5Y48.06%
Revenue Next Year62.32%
Revenue Next 2Y160.11%
Revenue Next 3Y226.72%
Revenue Next 5Y3.12%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
IMMP reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year IMMP is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
IMMP's earnings are expected to grow with 36.63% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y27.62%
EPS Next 3Y36.63%
5. Dividend
5.1 Amount
No dividends for IMMP!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
IMMUTEP LTD-SP ADR
NASDAQ:IMMP (5/3/2024, 7:00:02 PM)
After market: 2.75 -0.07 (-2.48%)2.82
+0.13 (+4.83%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap335.25M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -27.06% | ||
| ROE | -29.23% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 13.81 | ||
| Quick Ratio | 13.81 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-19.67%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y27.02%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-50.1%
Revenue growth 3Y-76.04%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y